Jasper Therapeutics, Inc. ( (JSPR) ) has released its Q3 earnings. Here is a breakdown of the information Jasper Therapeutics, Inc. presented to its investors.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117), to treat mast cell and stem cell diseases, such as chronic urticaria and asthma, with ongoing clinical studies for these conditions.
In the third quarter of 2024, Jasper Therapeutics reported significant milestones in their mast cell development programs, including positive initial data from the SPOTLIGHT study for chronic inducible urticaria and regulatory clearance for further studies in asthma and chronic urticaria. Additionally, they announced the closure of their legacy clinical study in lower-risk myelodysplastic syndromes.
Key financial highlights from the quarter include a net loss of $18.6 million, with research and development expenses totaling $14.5 million and general and administrative expenses amounting to $5.4 million. The company holds $92.5 million in cash and cash equivalents. Strategically, the company is advancing its SPOTLIGHT and BEACON studies, expanding to higher dose cohorts, and preparing for future presentations of data in early 2025.
Despite reporting a net loss, Jasper Therapeutics continues to make progress in its clinical programs, with an optimistic outlook on upcoming data presentations and further development of briquilimab as a treatment for chronic urticaria and asthma.
